Biomerica (NASDAQ:BMRA – Get Free Report) and XORTX Therapeutics (NASDAQ:XRTX – Get Free Report) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their dividends, analyst recommendations, risk, valuation, profitability, institutional ownership and earnings.
Analyst Recommendations
This is a breakdown of current ratings for Biomerica and XORTX Therapeutics, as reported by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Biomerica | 1 | 0 | 0 | 0 | 1.00 |
| XORTX Therapeutics | 1 | 0 | 0 | 0 | 1.00 |
Biomerica presently has a consensus target price of $9.00, indicating a potential upside of 462.50%. Given Biomerica’s higher probable upside, equities analysts plainly believe Biomerica is more favorable than XORTX Therapeutics.
Profitability
| Net Margins | Return on Equity | Return on Assets | |
| Biomerica | -96.49% | -98.14% | -70.42% |
| XORTX Therapeutics | N/A | -150.01% | -106.53% |
Earnings & Valuation
This table compares Biomerica and XORTX Therapeutics”s top-line revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Biomerica | $5.31 million | 0.93 | -$4.97 million | ($0.89) | -1.80 |
| XORTX Therapeutics | N/A | N/A | -$2.66 million | ($2.63) | -0.80 |
XORTX Therapeutics has lower revenue, but higher earnings than Biomerica. Biomerica is trading at a lower price-to-earnings ratio than XORTX Therapeutics, indicating that it is currently the more affordable of the two stocks.
Institutional & Insider Ownership
22.3% of Biomerica shares are held by institutional investors. Comparatively, 0.2% of XORTX Therapeutics shares are held by institutional investors. 18.0% of Biomerica shares are held by company insiders. Comparatively, 6.9% of XORTX Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.
Volatility & Risk
Biomerica has a beta of 0.33, indicating that its share price is 67% less volatile than the S&P 500. Comparatively, XORTX Therapeutics has a beta of 0.74, indicating that its share price is 26% less volatile than the S&P 500.
Summary
Biomerica beats XORTX Therapeutics on 7 of the 11 factors compared between the two stocks.
About Biomerica
Biomerica, Inc., a biomedical technology company, develops, patents, manufactures, and markets diagnostic and therapeutic products for the detection and/or treatment of medical conditions and diseases worldwide. The company's diagnostic test kits are used to analyze blood, urine, nasal or fecal specimens from patients in the diagnosis of various diseases, food intolerances, and other medical complications; or to measure bacteria, hormones, antibodies, antigens, or other substances which may exist in the human body, stools, or blood in extremely small concentrations. It primarily sells its products for gastrointestinal diseases, food intolerances, and various esoteric tests at the physicians' offices and over-the-counter drugstores, and hospital/clinical laboratories. The company is also developing InFoods IBS, that uses a simple blood sample to identify patient-specific foods which may alleviate irritable bowel syndrome symptoms; and H. Pylori diagnostic test that indicates if a patient is infected with the H. Pylori bacteria. In addition, it develops products to indicate if a person has been infected by COVID-19. Biomerica, Inc. was incorporated in 1971 and is headquartered in Irvine, California.
About XORTX Therapeutics
Xyratex Ltd (Xyratex) is a provider of data storage technology, including modular solutions for the enterprise data storage industry and hard disk drive (HDD) capital equipment for the HDD industry. Xyratex operates in two segments: Networked Storage Solutions (NSS) and Storage Infrastructure (SI). Its NSS products are primarily HDD based data storage subsystems and solutions, which it provides to original equipment manufacturers. Its SI products consist of HDD manufacturing process equipment, which it sells directly to manufacturers of HDDs and their component suppliers. Its product and solution portfolio for the enterprise data storage industry includes storage enclosures, integrated application platforms and high performance computing (HPC) data storage solutions. In April 2014, Seagate Technology PLC completed the acquisition of Xyratex Ltd.
Receive News & Ratings for Biomerica Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Biomerica and related companies with MarketBeat.com's FREE daily email newsletter.
